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Hereditary Colon Cancer: Molecular Research
and Family Studies Aim for Early Detection
by Bruce M. Boman, M.D., Ph.D.
Assistant Professor of Medicine
Section of Gastrointestinal
Oncology and Digestive Diseases
Colon cancer, the single most
common form of internal malignant
disease in the United States, ranks
second as a cause of cancer death.
Clinical studies attempting to
identify factors that contribute to
the development of colon cancer Dr. Bruce M. Boman
have shown that 10% to 15% of
patients with colorectal carcinoma have a family history of the
disease. Well--defined hereditary forms, which have an autosomal
dominant mode of inheritance, include the familial polyposis
and nonpolyposis colon cancer syndromes. In the general popu,
lation, first.-degree relatives of colorectal cancer patients have
a two, to threefold increased risk of developing colon cancer,
but the inheritance patterns are not well understood.

Research and Clinical Collaboration
Several clinical investigators and basic researchers at
M. D. Anderson Hospital are collaborating in a study of the
hereditary aspects of colon cancer. The major goals of the
program are (1) prevention or early detection of colon cancer
by screening persons who are at high risk of developing the
disease, (2) performing clinical genetic analyses of colorectal
cancer patients' families to identify families who may have a
genetic predisposition to the disease, and (3) performing
molecular and cytogenetic studies that may yield information
on the mechanisms of colon carcinogenesis or provide
molecular markers for identifying individuals at high risk of
developing the disease.

Familial Polyposis
In familial polyposis, patients develop multiple adenomatous
polyps of the colon and rectum at an early age. The incidence
of the disease is one in 7,000 to 10,000 live births.
In affected patients the risk of developing colon cancer
approaches 100% by age 45. Several extracolonic lesions may
occur in association with familial polyposis. Best known are
those of the Gardner syndrome, which consists of osteomas,
epidermoid cysts, fibromas, desmoid tumors, and abnormal
dentition. The Oldfield syndrome is the association of familial

polyposis with sebaceous cysts. Other lesions that may occur
in association with familial polyposis include gastric and
duodenal polyps and congenital hypertrophy of the retinal
i>igment ~pithelium.
In examining patients in MDAH's Special Risk Clinic,
physicians evaluate familial polyposis patients for these
possible extracolonic manifestations. In addition, the patients
are referred to the Department of Dental Oncology for a
dental examination, including a panoramic X ray of the
mandible and teeth, and to Baylor College of Medicine's
Cullen Eye Institute for opthalmologic evaluation with
particular attention to possible congenital hypertrophy of the
retinal pigment epithelium.
Since these extracolonic manifestations are associated with
familial polyposis, their presence may help identify family
members with the cancer,prone genotype before premalignant
colonic polyps appear.

Nonpolyposis Syndromes
Nonpolyposis colon cancer syndromes, including hereditary
site-specific colon cancer syndrome and cancer family syndrome,
also are marked by the development of colon cancer at an
early age. Although these syndromes are subclassified as
nonpolyposis variants, an inherited tendency to develop
discrete adenomatous polyps is present in some families. The
cancer family syndrome carries an increased risk of cancers of
many types, but colon and endometrial malignancies
predominate.

Special Risk Clinic
The MDAH Special Risk Clinic was established by Rodger
Winn, M.D., director of the Community Oncology Program,
to monitor patients whose risk of developing this disease is
substantially higher than that of the rest of the population.
Clinical criteria of increased risk include histories of
1. two or more relatives in the immediate family (parents,
siblings, or children) who have colon cancer,
2. familial polyposis or the Gardner syndrome occurring in
the family,
3. heterogeneous tumors in one,fourth or more immediate
family members,
4. multiple primary colon cancers or a primary colon cancer
that developed in the person before age 40.

continued on page 4
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Houston-Galveston H ybridoma Researchers
Review Laboratory and Clinical Progress
by Frances M. Davis, Ph.D.

producing cells are segregated, each produces a clone of cells.
The antibodies secreted by these cell clones are the monoclonal
antibodies. The method of producing these was first described
by Cambridge scientists Georges Kohler and Cesar Milstein in
197 5; nine years later they won a Nobel Prize for their work.
Another type of hybridoma cell is produced by the fusion of
T lymphocytes with tumor cells. Like normal cells, these T-T
hybridomas secrete signal molecules-lymphokines-that regulate the activity of the immune system.

Department of Chemotherapy Research
Hybridoma technology is one of
the most rapidly developing areas
in biological research, with new
methods to improve hybridoma yield
and new uses for the cell products
appearing almost daily in the scientific literature. These advances made
the Second Texas Medical Center
Hybridoma Symposium, held last Dr. Frances
April at UT MDAH, an optimistic
forum for Houston-Galveston researchers.

Clinical Usefulness Becoming Evident
M. Davis

Hybridoma Cell Types
The most common type of hybridoma cell is formed by the
fusion of normal antibody-producing cells with immortal tumor
cells. These hybridoma cells reproduce continuously in a laboratory dish and secrete antibodies. When individual antibody-
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The monoclonal antibodies and lymphokines secreted by the
hybridoma cells have enormous potential usefulness in the
diagnosis and treatment of cancer. One method of using
hybridoma technology in diagnosis is to attach radioactive
chemicals to the antibodies and infuse them into patients.
Because the antibodies seek out and bind to cells that have
corresponding molecules on their surface, radioactive areas in
the patient's body can then be spotted by scintigraphic
scanning and the sites of tumor nodules identified. For treatment, radiation may be delivered to the tumor by radioactive
molecules attached to antibodies, and chemotherapeutic agents
may be delivered the same way.
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Hopeful Reports
Of the 14 papers presented at the one-day conference, 11
described work being done at UT MDAH. Susan M. North,
Ph.D., who reported work on metastatic mammary carcinoma
in the rat, said that her group in the Department of Tumor
Biolo has used monoclonal antibodies to inhibit metastasis
a long step up from identifying and characterizing metastasisrelated surface antigens. North has found also that the
monoclonal antibodies bind to similar antigens in some human
breast cancers.
Discussions of clinical investigations dealt with using
monoclonal antibodies in immunoscintigraphy to locate
metastatic cancers. James L. Murray III, M.D., and Richard J.
Babaian, M.D., led a discussion of the potential value and
problems of this new diagnostic modality. In collaborations that
involved staff members of the MDAH Departments of Clinical
Immunology and Biological Therapy, Urology, Medical OncoOctober-December 1986

logy, and Nuclear Medicine, these investigators used a
monoclonal antibody to a carcinoembryonic antigen to local,
ize colorectal tumors and a monoclonal antibody to a prostate
antigen to scan for metastatic prostate cancer.
A description of several new antibodies specific for human
colon cancer cells came from Benjamin Drewinko, M.D., Ph.D.,
and coworkers Li,Ying K. Yang and Jae Y. Ro, M.D. , Ph.D.,
of the Division of Laboratory Medicine. Because of the
antigenic heterogeneity of cancers, mixtures of several
monoclonal antibodies that bind to the same tumor cells may
be more effective for diagnosis and therapy than one monoclonal
antibody alone, which places a high value on finding new tumor,
associated markers.

Need Human Antibodies
Most of the monoclonal antibodies produced so far originate
in rodents, and the need for repeated infusions of antibodies
for scanning and therapy is a compelling reason for developing,
human monoclonal antibodies. Human antibodies to tumor,
associated antigens are needed also to study the immune
response to cancer. Ruth Carsetti, M.D., described work in the
gynecology department laboratory, in collaboration with Ralph
S. Freedman, M.D., with lymphocytes from patients who have
ovarian cancer and are immunized with oncolysates of their own
tumors to produce monoclonal antibodies specific to these
tumors.

Basic Scientific Advances
James C. Chan, Ph.D., who chaired the symposium, described
collaborative studies in which epitopes, also known as anti,

genie determinants, are mapped using a panel of monoclonal
antibodies to carcinoembryonic antigen. His group also
compared the activity of antibodies from commercial sources
with that of antibodies generated at UT MDAH.
Chintaman G. Sahasrabuddhe, Ph.D., reported preparation
of monoclonal antibodies to B,cell growth factor, a lymphokine
that stimulates proliferation of antibody,producing cells. These
antibodies may be used to purify the lymphokine and to study
its regulation and mechanism of action.
I reported on my study with Potu N. Rao, Ph.D., in which
we use monoclonal antibodies to investigate the process of
mitosis. We have identified and defined several mitosis,specific
antigens with this method. We are using these antibodies to
investigate how a cell accomplishes its reorganization at each
mitosis, when the nuclear membrane breaks down, the
chromatin condenses into chromosomes, and the cytoskeleton
is mobilized to segregate the chromosomes to the two daughter
cells. In addition, the proportion of mitotic cells in biopsied
tumor tissue is often used for tumor staging, and these
antibodies can be used to identify mitotic cells.
That our discussions moved from laboratory findings to
clinical uses is one indication of how far hybridoma research
has come. We hope to organize the third hybridoma
symposium for this area early next year.

Physicians who desire additional information may write Frances
M. Davis, Ph.D., Department of Chemotherapy Research, Box 52,
The University of Texas M. D. Anderson Hospital and Tumor
Institute at Houston, 6723 Bertner Avenue, Houston, Texas
77030.

Celebrate the Season with Pediatric Christmas Cards
The annual sale of Christmas cards designed by UT MDAH pediatric patients is under way and offers an
expanded selection this year, including two new deluxe designs (one featuring a sesquicentennial motif), a
gift tag design, and the Collector's Edition-an assortment of cards from past years. Note cards for use year,
- - 1--~-S:..i-l-- - ~ ~- -r-o-un
~ _:_a_r_e_a~so_ a_v~ai ab e.
Volunteer Services, which sponsors the yearly sale, sold a record 2.5 million cards last year. Funds earned
from the sale support special activities for the pediatric patients -summer camp and a Colorado ski trip, for
example-and they bolster other pediatric programs by providing supervisors, a Spanish,speaking interpreter,
school supplies for classes taught at the hospital, and a homelike cottage that provides a place for families
to stay together while the children undergo treatment. Fifteen college schol~rships and five vocational
scholarships are also made possible by the card sales. Sets of cards range in cost from $7 to $10. For an order
form and a brochure showing the cards, write M. D. Anderson Volunteer Services, Box 114, 6723 Bettner
Avenue, Houston, Texas 77030.
Vol. 31, No. 4
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continued from page 1
Surveillance of these patients requires the collaboration of
several clinical services. The preventive oncologists and their
staff members, under Winn's direction, take the medical and
family histories and perform a physical examination that
includes a digital rectal examination, fecal occult blood test,
blood analysis, and a chest roentgenogram.
The medical history includes information relating to gastrointestinal symptoms, extracolonic manifestations associated with
familial polyposis, and any individual history of polyps or cancer.
This information is being collected as the Special Risk Clinic
data base. We intend to integrate this data base with others
at Anderson Hospital including the health survey data base of
the Department of Cancer Prevention, the colorectal surgical
data base of the Section of Gastrointestinal Surgery, and the

endoscopy data base established by the Section of Gastrointestinal Oncology and Digestive Diseases in collaboration with the
American Society for Gastrointestinal Endoscopy.
A detailed family history is elicited from each patient referred
to the Special Risk Clinic, and the information is reviewed and
interpreted by Louise Strong, M.D., Sue and Radcliffe Killam
Professor of Genetics. The family history includes information
on all of the patient's first-degree relatives-'-their medical
history and current age or age at death.
In collecting the family history, it is as important to include
individuals who have no history of colon cancer as it is to
include those who have or had this illness. W ith information
on all individuals at risk in a family, it is possible to determine
the probability of cancer, colon cancer in particular, occurring
by chance or according to some specific genetic or environmental model.
For families in which close relatives have or had colon cancer,

History of a Patient
A 44-year-old woman with a history of familial polyposis was
seen at M. D. Anderson Hospital for evaluation of an acute
episode of rectal bleeding. Eighteen years ago, when she
experienced abdominal discomfort and rectal bleeding, she had
been diagnosed as having familial polyposis. At that time,
proctoscopic examination and a barium enema had revealed

numerous colorectal polyps. She had been treated with a total
abdominal colectomy with an ileoproctostomy. Pathologic
examination of the resected colon had shown many adenomatous polyps (Fig. 1), one polyp containing carcinoma in
situ. Since then her annual screenin g had included a
proctosigmoidoscopic examination; any polyps found in the
retained rectal segment were removed. She had been in good
health except for the recent episode of rectal bleeding.

Illness Affected Mother, Sister, Daughter

Fig. 1. Adenomatous polyps in resected colon of patient who sought
treatment because of abdominal pain and rectal bleeding. Familial
polyposis was diagnosed on the basis of medical and family history,
proctoscopic examination, and barium enema. A total abdominal
colectomy with ileorectostomy was performed because of the patient's
100% risk of colon cancer. One polyp proved to have carcinoma in
situ. (From Boman and Levin, Familial polyposis, Hospital Practice,
May 15, 1986, copyright /986 by HP Publishing Company. Reprinted
with permission.)
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The patient's family history (Fig. 2) was remarkable in that
her mother had died at age 36 of generalized sepsis secondary
to a perirectal abscess, which, considered in retrospect, may
have been an undiagnosed rectal cancer. One of the patient's
sisters had also been found to have polyposis of the colon at
age 28; a total colectomy with ileorectal anastomosis had been
rfunned, and two--syndn.onoas colon carcinomas had bee-n--- - - found in the resected colon. She had died at age 37 of metastatic
colon cancer.
When the patient's three children were screened, the oldest
daughter, 15, was diagnosed as having familial polyposis. A
total colectomy with ileorectal anastomosis was performed the
following year, and no evidence of malignancy was found. She
continues to have semiannual medical evaluations.
A nephew is reported to have multiple polyposis of the colon.

Patient's Examination and Treatment
A detailed ophthalmoscopic examination showed the patient
to have bilateral hypertrophic lesions of the retinal pigment
epithelium (Fig. 3). A radiographic bone survey showed an
October-December 1986

we obtain a more extended family history to determine the most
likely genetic or environmental model that can account for the
familial aggregation. We construct pedigrees from the family
history and counsel patients who are at high risk of colon
cancer about their risk and the need for screening.

Surveillance
The screening program for patients involves an endoscopic
procedure that is performed by Bernard Levin, M.D., Robert
R. Herring Professor and chief of the Section of Gastrointestinal Oncology and Digestive Diseases, and other physicians in
that section. The specific recommendations for endoscopy
depend on the patient's cancer risk. ln tamilies that have one
of the well-defined hereditary syndromes, members who inherit
that trait have a nearly 100% risk of developing cancer. In
persons with familial polyposis syndromes, the polyps usually
occur in the second decade of life, which is why annual
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flexible sigmoidoscopy examinations are usually begun at age
14. In persons who have the nonpolyposis syndromes, the risk
of cancer begins in the third decade, so that annual flexible
sigmoidoscopy exams are recommended from age 20 on.
In the general population, in contrast, the risk of colon cancer
begins at age 40. Not considered at high risk, this group is not
screened by the MDAH Special Risk Clinic. Nevertheless, all
standard-risk asymptomatic persons should follow the recommendations for screening established by the American Cancer
Society and distributed by the Texas Division of the American
Cancer Society Colorectal Task Force: an annual digital rectal
exam, beginning at age 40; an annual stool blood test,
beginning at age 50; and a proctosigmoidoscopic exam every
three to five years after two initial negative annual exams are
done at age 50 and 51.

continued on page 8

The patient's ileum was resected and another ileostomy was
established; pathologic examination showed cancerous invasion
through the bowel wall and metastatic disease in one of 14
regional lymph nodes. A year later, the patient developed
locally recurrent metastatic carcinoma of the pelvis. She was
treated with systemic chemotherapy but died of recurrent cancer
at age 51.

Fig. 2. Family pedigree of the patient (proband) details findings of
more than three generations. (Prepared with the assistance of
Louise C. Strong, M.D.)

osteoma in the proximal fibula. Proctoscopic examination
revealed a 4-cm villous adenomatous polyp in the retained
rectal segment.
She was treated surgically with a proctectomy and ileostomy; the pathologic examination showed an adenocarcinoma
arising in the villous adenoma with invasion of the inner half
of the muscularis propria. Lymph node involvement ~as not
evident.
The pati~nt continued to be screened after the o~tion. Two
years later, she was found to have a villous adenoma of the
periampullary region. A subtotal gastrectomy was performed and
no evidence of malignancy found. But the patient developed
recurrent bleeding from the ileostomy, and ileoscopic
examination revealed an adenocarcinoma of the ileum arising
in a large ileal polyp.

Vol. 31, No. 4

_ Eig._3. Congenital b_yp_ectmphy aLtbe_cetinal pigment epitb_elium_is
closely linked to the familial polyposis trait in some kindreds. Retinal
lesions are asymptomatic and tend to occur in patches in one or both
eyes. The patient discussed in the family history had lesions in the
central portion of the retina in one eye and on the periphery in the other
(arrows). (From Boman and Levin, Familial polyposis, Hospital
Practice, May 15, 1986, copyright /986 by HP Publishing Company.
Reprinted with permission.)
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Bone Marrow Transplantation Success
Brings Patients and Physicians to Reunion
Last June 40 patients who had undergone bone marrow
transplantations at UT MDAH came to a hospital reunion to
celebrate their improving health after having had leukemia,
lymphoma, myeloma, or a solid-tumor type of lung cancer.
To be able to see so many well-functioning transplantation
patients all at once made the reunion a grand affair for Karel
A. Dicke, M.D., professor of medicine and chief of the Bone
Marrow Transplantation Center since 1975.
Since Dicke came from the Netherlands to head the
program, transplantations have multiplied from one a year to
145 last year. In the last 10 years, 700 patients ranging in age
from 4 to 69 years received bone marrow transplants at UT
MDAH. Currently, about 200 patients are alive six months or
longer after the procedure, seven years being the longest survival.
Bone marrow transplantation-done to restore a patient's
hematopoietic system after it is deliberately disturbed by highdose cytoreductive therapy-has become a subspecialty with
complexities and problems that must be solved by research,
Dicke said, and one that is well served by interinstitutional and
international collaborations. In 1984, the Anderson people
organized the first international symposium on autologous bone
marrow transplantation (ABMTI, and they will host the third
one in Houston December 4-5 (the second was in Parma,
Italy), and perhaps the fourth in 1988.
Autologous transplantation has surpassed allogeneic transplantation, Dicke explained. This is so because only 10% to 15%
of the patient population is eligible for sibling-to-sibling transplants, and because methods of purging bone marrow of neoplastic cells by high-dose chemotherapy and of testing bone
marrow for the absence of cancer cells have improved much
over the years.

Detecting Tumor Cells in Bone Marrow
On the horizon are new laborato techni ues to assure that the
bone marrow is free of cancer cells.
Two of these were developed by
Mary Jean Hodges, Ph.D., and
Christopher L. Reading, Ph.D., both
researchers in the Bone Marrow
Transplantation Center.
Hodges works with Joel Bressler,
Ph.D., of the Department of Clinical
Immunology and Biological Therapy
to develop for clinical practice a
method by which oncogenes are
6

used to detect abnormal, and therefore cancerous, gene expression in
bone marrow cells.
"We are at the point at which
we do this routinely in the lab
with bone marrow samples from
patients," Hodges said. "We can
detect any gene or any virus we
want to look at, and we hope that
the technique will be applicable
whenever one needs to detect
Dr. Christopher L. Reading disease that may be present in only
a small proportion of cells.''
One drawback of the methods available now, she said, is low
sensitivity. "With current methods, we can tell whether a
particular gene is being expressed in tissue, but it has to be
present at fairly high levels. With the method we are
developing, with oncogenes as probes, we can detect one
abnormal gene in a million cells if we need to."
In Reading's laboratory, the researchers use monoclonal
antibodies that react specifically with different cell types in
the bone marrow.

In 10 years, 700 patients received
bone marrow transplants at UT MDAH.
After treatment with the monoclonal antibody, Reading
explained, cells are treated with a magnetic-affinity colloid, a
reagent he developed. This colloid binds to the antibodyreactive cells. The cell mixture is then passed through a
column of screens magnetized by a sammarium cobalt magnet.
e positive cells_are____retaineQJn the steeLsrreen aod t~
negative cells flow through and into a syringe.
The procedure, Reading said, "has worked consistently well.
The system can be used to remove antibody-reactive cells, and
it can be used to deplete bone marrow of mature T cells in
allogeneic transplantation or to purge tumor cells from
autologous bone marrow. After six years of development, this
magnetic removal of tumor cells is ready for clinical use."

Improved Results in Leukemia Patients
Dr. Mary Jean Hodges

For the short term, last year's ABMT program achieved
good results for patients with acute myelogenous leukemia.
October-December 1986

Since then, we have treated 30 more patients with ABMT, and
the results are holding."

International Collaborations
The international symposia are tightening connections
between bone marrow specialists everywhere. Dicke and the
Nebraskans are working with physicians in France and the
Netherlands-Thierry Philip, M.D., of Lyons and Ton Hagenbeek, M.D., of Rotterdam-to study the effect of high-dose
chemotherapy in patients with non-Hodgkin's lymphoma who
have relapsed but are responding to normal-dose chemotherapy. One aspect of the program, just beginning, is "involvedfield irradiation," which means that, instead of the whole body,
primary areas of disease involvement-usually the mediastinum
or abdomen-are irradiated before transplantation.
Dr. Karel Dicke (center) with Mariam Young of Clarksville, Tenn., who
came to reunion o f bone marrow transplantation patients with her son,
Dr. M orris Young.

"Among 17 patients, the projected 18-month disease-free
survival is 75%," Dicke said, "although patient selection
might be one of the reasons for this promising result(' The
study was not truly randomized, he explained, because patients
needed to volunteer for it and the volunteers turned out to be
patients in good condition.
"Selection is a difficult problem," Dicke said. "We tried to
do it as a randomized study, but at that time the patients did
not want to enter the transplantation program. Now it is the
other way around-patients like to have transplantation, now
that they see the remissions it can produce."
Transplantation results for patients with acute lymphocytic
leukemia have also improved, he said, ''because the normal
chemotherapy that precedes the high-dose program has become
excellent. At the time the marrow is collected, therefore, the
leukemic cell count may be very low, so that few leukemic cells
are reinfused into the patient."
A t UT MDAH, he said, the most effective high-dose
chemotherapeutic program for patients with acute leukemia has
turned out to be CBV, a combination of cyclophosphamide,
BCNU (carmustine), and VP-16-213 (etoposide). In some cases,
it is administered twice to strengthen and lengthen the
patient's remission. Then, three months after the patient has
undergone the first high-dose chemotherapy program and
ABMT, Dicke explained, another high-dose chemotherapy
regimen is administered. "In our hands," Dicke said, "CBV
seems to be very active in acute leukemia."
For patients who have relapsed with Hodgkin's disease, the
MDAH team has a collaborative program with a University of
Nebraska team headed by James Armitage, M.D. "We have
treated 60 patients among whom the complete remission rate
is 47%," Dicke said. "Our first results with 30 patients were
published in the Annals of Internal Medicine early this year.
Vol. 31, No. 4

Results for patients with acute
lymphocytic leukemia have also improved.
New Breast Cancer Protocol
For patients with stage IV breast cancer who respond to
normal-dose chemotherapy, Dicke is studying a new protocol
that consists of bone marrow removal, high-dose chemotherapy, bone marrow transplantation, a repeat course of highdose chemotherapy, and a second ABMT procedure. ''We did
this for lung cancer patients with little success," he said, "but
it is new for patients with breast cancer. We have treated 10
patients so far and have seen good responses, but we have no
idea how long the responses will last. It is encouraging, though,
to have patients come in with nodules of the skin and to see
these disappear."
Dicke stressed that the breast cancer high-dose chemotherapy and transplantation program is useful only for patients who
respond to normal chemotherapy. Nonresponding patients are
not likely to gain anything from such risky treatment.
''We have to look at the benefit-risk ratio for all our patients,''
Dicke said. "It is crucial for us to ask: what does a patient gain
from a high-dose program to be worth the suffering that high
doses of chemicals often cause? If we can change the natural
history of the disease with chemotherapy, and in some cases
with radiotherapy-and use bone marrow transplantation to
protect the patient's hematopoietic mechanisms-that makes
it worth the pain these patients often experience."

Physicians who desire additional informa,tion may write Karel
A Dicke, M.D., Section of Bone Marrow Transplantation,
Department of Hematology, Box 55, The University of Texas
M. D. Anderson Hospital and Tumor Institute at Houston,
6723 Bertner Avenue, Houston, Texas 77030.
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Hereditary Colon Cancer
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continued from page 5

Management
Endoscopic examination and surgical intervention are the
main techniques designed to eliminate the risk of colon cancer
in patients with a defined hereditary syndrome. Because cancers
usually arise from adenomatous polyps in these patients, the
cancer risk is related to the number of polyps present. A few
polyps can be endoscopically removed, but most patients will
require surgical removal of the colon at the time of diagnosis.
For patients with this syndrome, the surgical options, depending
on the number of polyps in colon and rectum, include abdominal
colectomy with ileorectal anastomosis, abdominal colectomy
with mucosal proctectomy and reservoir ileoanal anastomosis,
or total proctocolectomy with an ileostomy.

Colon cancer ranks second
as a cause of cancer death.
Molecular Genetic Studies
Since the identification of people who have a genetic
predisposition to colon cancer provides an opportunity for
prevention, basic research is being done to identify genetic
markers associated with hereditary colon cancer. Staff members
of the Section of Cellular Genetics analyze chromosomes of cells
isolated from these patients, hoping to identify a specific
chromosomal defect associated with the disease. Other
researchers in the section study the susceptibility of cultured
lymphocytes to mutagens to detect possible chromosomal
instability in these patients.

8

My research involves the use of molecular biologic methods
to try to identify a chromosome that contains a major gene
associated with the inherited predisposition to colon cancer.
One study, performed in my laboratory by David Wildrick,
Ph.D., involves analysis of DNA isolated from normal and
colon cancer tissues by Southern (DNA) blot hybridization to
determine whether heterozygous gene loci on a specific
chromosome are reduced to homozygosity in the tumor. If
tumor-specific loss of heterozygous loci were detected, this would
suggest that the chromosome to which these loci are mapped
might contain a major gene associated with colon cancer.
In another of our laboratory projects, normal and malignant
cells from hereditary colon cancer patients are cultured, and
molecular methods are used to clone a complementary DNA
library from mRNA isolated from these cell cultures. We plan
to use differential gene screening to detect possible gene loss
or gene activation in the colon carcinoma cells compared with
that in normal colonic epithelial cells.
we succee m etectmg a genetic mar er assoc1a e w1
the hereditary predisposition to colon cancer, it should be
useful for genetic counseling, including carrier detect ion and
prenatal diagnosis in high-risk families. Moveover, identifica,
tion of the chromosome that harbors such a gene could
eventually lead to the successful cloning of a colon cancer gene.
The molecular characterization of the gene and its protein
products is likely to provide insight into the mechanisms of
colon carcinogenesis and thus lead to possible strategies for
therapeutic intervention.

Physicians who desire additional infonnation may unite Bruce M.
Boman, M.D., Ph.D., Section of Gastrointestinal Oncology and
Digestive Diseases, Box 68, The University of Texas M.D.
Anderson Hospital and Tumor Institute at Houston, 6723 Bertner
Avenue, Houston, Texas 77030.
October-December 1986

